CRX.L Regulatory News (CRX)

20 Apr 2005 07:00

Cyprotex PLC20 April 2005 Press Release 20 April 2005 Cyprotex launches innovative new screening service for assessing cardiovascular toxicity Cyprotex Plc has launched a new innovative screening service, Cloe Screen(R)HERG Safety, for the early and rapid assessment of cardiovascular toxicity.Contracts for the supply of this new service have already been entered into withUS based customers. Cyprotex's Cloe Screen(R) HERG Safety is the first automated electrophysiologyhigh throughput service that provides direct evaluation of ion channels,quantifies dose-response and delivers data on the degree of HERG inhibition andpotential cardiac toxicity potency. With Cloe Screen(R) HERG Safety Assay theseimportant results are now both consistently accurate and reproducible. Commenting on the launch of this new service, Robert Atwater, Chairman and CEOof Cyprotex said: "The Cloe Screen(R) HERG Safety assay provides a new highthroughput approach providing unrivalled efficiency for our partners. Thistechnology delivers a 50 fold increase in efficiency over the gold standardsingle cell patch clamp method, without compromising data integrity - and thischanges the entire economics of HERG toxicity screening. This exciting newtechnology ensures the identification of issues earlier in the drug discoveryprocess before significant and unnecessary costs and time are invested infurther drug development." For further information: Cyprotex PLCRobert Morrisson Atwater, Chief Executive Officer Tel: +44 (0) 1625 505 100ir@cyprotex.com www.cyprotex.com Code Securities LimitedChris Collins Tel: +44 (0) 20 7024 2000cic@codesecurities.com www.codesecurities.com Media enquiries: Abchurch Communications LimitedHenry Harrison-Topham / Heather Salmond Tel: +44 (0) 20 7398 7700heather.salmond@abchurch-group.com www.abchurch-group.com This information is provided by RNS The company news service from the London Stock Exchange